26 results about "Pancreatic duct" patented technology

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses a self-breaking outer drainage tube, and relates to the technical field of medical instruments, the self-breaking outer drainage tube comprises a tube body, and the tube body comprises a drainage part, a breaking part, a leading-out part and a puncture part; the drainage part and the fracture part are both made of degradable materials; the hole wall thickness of the circulation hole at the fracture part is smaller than the hole wall thickness of the circulation hole at the drainage part; during surgical operation, the degradable inner drainage part is placed in the pancreatic duct, the fracture part crosses the anastomotic stoma by 7-8 cm and crosses the biliary-intestinal anastomotic stoma, and the leading-out part walks in the enteric cavity to a proper position, penetrates out of the intestinal wall and is led out of the body through the abdominal wall. Cutting the puncture part to expose the outlet of the circulation hole, and discharging the body fluid through the circulation hole; after a certain period of time after the operation, the fracture part is automatically fractured under the action of pancreatic juice, the leading-out part is pulled out, the degradable drainage part continues to be degraded in the body and maintains the drainage function, and finally the drainage part is absorbed by the body or discharged out of the body without being taken out through the operation.

A medical image processing apparatus according to an embodiment includes processing circuitry. The processing circuitry is configured to obtain a medical image related to the pancreas. The processing circuitry is configured to extract a pancreas region included in the medical image. The processing circuitry is configured to extract at least one tubular structure region from the inside of the pancreas region. The processing circuitry is configured to identify a first end part and a second end part related to the pancreas on the basis of the pancreas region. The processing circuitry is configured to estimate a primary pancreatic duct centerline of the pancreas on the basis of the tubular structure region, the first end part, and the second end part.

To provide a device for an endoscope improved in insertability when inserting a treatment instrument into a biliopancreatic duct.SOLUTION: An endoscopic device includes a sheath extending in a longitudinal direction, a treatment tool opening portion communicating with a treatment tool lumen through which the sheath is inserted in the longitudinal direction and configured to allow a treatment tool inserted through the treatment tool lumen to protrude and retract to and from a distal end side of the sheath in the longitudinal direction, and a suction opening portion communicating with a suction lumen through which the sheath is inserted in the longitudinal direction.SELECTED DRAWING: Figure 3

The utility model belongs to the technical field of drainage tubes, and particularly relates to a pancreatic duct supporting drainage tube for pancreatic surgery, which comprises a drainage main tube and a sleeve, one end of the drainage main tube is detachably connected with the sleeve through a first connecting component, a supporting component is arranged in the drainage main tube, a fixing component is arranged on the sleeve, and the fixing component is detachably connected with the sleeve through a second connecting component. The fixing assembly and the supporting assembly are detachably connected together through the second connecting assembly. The first connecting assembly comprises a first annular plate, the first annular plate is fixedly installed at one end of the drainage main pipe, and a first annular groove is formed in the left side of the sleeve. The supporting assembly is arranged in the drainage main pipe, and the fixing assembly is arranged on the sleeve, so that when the pancreas surgery is carried out, the drainage main pipe can be prevented from being flattened, the position of the sleeve can be fixed, and the situation that the drainage main pipe is blocked due to extrusion can be avoided.

The invention belongs to the field of biomedical materials, and particularly relates to an inner drainage end-by-end reducer tube based on the electrostatic spinning technology and a preparation method thereof.The inner drainage end-by-end reducer tube comprises an end-by-end reducing drainage tube, the whole drainage tube is of a hollow conical tubular structure, and the surface of the drainage tube is provided with regularly-arranged thread structures; the invention further provides a preparation method of the inner drainage end-by-end reducer pipe. The defects of existing internal drainage are overcome, and the natural anatomical form of the pancreatic duct is complied with by means of the drainage tube with the diameter changed end by end; the drainage tube is provided with a surface thread structure, and by matching with the swelling characteristic of a biodegradable material, the friction force between the drainage tube and the pancreatic duct wall is increased, and the probability of displacement of the drainage tube due to intestinal tract movement or pancreatic juice scouring is reduced.

This invention provides a single-operated duodenal sphincter cutter, comprising: an outer sheath, a guidewire, a metal wire, and a handle. The guidewire is inserted into the interior of the outer sheath through its wall and exits from its tip. The handle is connected to the tail of the outer sheath. One end of the metal wire is fixedly connected to the front of the outer sheath, and the other end is inserted into the interior of the outer sheath and connected to the handle. This invention features a dual-channel tube, with the guidewire entering the guidewire channel through the side wall. Its outer diameter is thinner than that of a conventional three-channel tube. The guidewire is led out through the side wall of the tube. With the outer sheath fixed in place, the operator can insert the guidewire into the common bile duct or pancreatic duct without the assistance of an assistant, increasing the success rate of cannulation.

Biomarkers, systems, and methods for predicting a prognostic outcome of pancreatic duct adenocarcinoma (PDAC) and responsiveness of a cancer patient to a PARP inhibitor are provided. The metabolites biomarkers are used to predicting a prognostic outcome of PDAC, and includes one or more of LysoPC (14: 0), LysoPC (18: 2), LysoPC (18: 1), Androsterone sulfate, alpha-CEHC, Glycodeoxycholic acid sulfate, LysoPC (20: 5), LysoPE (22: 5), and LysoPE (16: 1). The gene biomarkers are used to identify cancer patients responsive to a PARP inhibitor, and includes one or more of CTNND1, THRAP3, BRAF, STAT5B, and EXT2.

The invention discloses a conical endoscope, and belongs to the technical field of medical instruments. Comprising an endoscope body, an incision knife assembly, a guide wire assembly and an expandable assembly, the endoscope body is of a conical design, the endoscope body is made of a polyurethane material, the length of the endoscope body is 2200 mm, and the diameter of the endoscope body is 8 mm; according to the conical endoscope, by means of the targeted structural design, the adaptability and operation convenience of clinical operations are remarkably improved. The endoscope has the core advantages that the combined design of the conical endoscope body and the inclined axis is adopted, and the frustum-shaped structure at the front end of the endoscope is matched with the 45-degree or 60-degree adjustable central axis, so that the endoscope can accurately adapt to the anatomical trend of narrow cavities such as human biliopancreatic ducts and the like, and compared with a traditional straight-tube endoscope, the endoscope can enter a target part more easily and smoothly, and mechanical damage to mucous membranes of the cavities is reduced. The adaptive capacity is further enhanced through the modular design of the expandable assembly, and the diameter adjustment of the four or more evenly-distributed annular protrusions is achieved through the expansion control device.

[Problem] To provide: a cannula that can be easily inserted into a common bile duct or a pancreatic duct via a major duodenal papilla; and an endoscopic system provided with such a cannula. [Solution] A second camera 30 of a cannula 12 captures an image of the entrance of a common bile duct or a pancreatic duct in a state where the second camera 30 is inserted from the opening of a major duodenal papilla. A transparent shield 124 provides a cavity around the second camera 30 and ensures a field of view Vf of the second camera 30 in a state where the transparent shield 124 is inserted from the opening. The shield 124 has a convex surface 124c around the central axis CA of the field of view Vf of the second camera 30. The portion having the convex surface 124c has a uniform thickness. A guide wire 15 is configured to advance within the field of view Vf of the second camera 30.

The invention belongs to the field of pancreatic duct adenocarcinoma prediction, and provides a pancreatic duct adenocarcinoma prediction method and system based on oral flora. The pancreatic ductal adenocarcinoma prediction method based on oral flora comprises the following steps: acquiring relative abundance information of each biomarker in a potential biomarker set for diagnosing pancreatic ductal adenocarcinoma of a to-be-detected person; using the relative abundance information of each biomarker in the biomarker set and a pre-trained multivariate statistical model to obtain a probability value of suffering from pancreatic ductal adenocarcinoma; the method comprises the following steps: performing microbiome difference analysis on saliva, duodenal juice and pancreatic tissue samples of a pancreatic ductal adenocarcinoma patient group and a pancreatic benign disease patient group, and taking an intersection of differential bacteria in the samples to obtain a potential biomarker set for diagnosing the pancreatic ductal adenocarcinoma.

Medical devices and method for making and using the same are disclosed. An example medical device may include implantable medical device for use along the biliary and / or pancreatic tract. The implantable medical device may include a tubular member having a first end configured to be disposed within the duodenum of a patient and a second end configured to be disposed adjacent to a pancreatic duct and / or bile duct. The tubular member may have a body including one or more wire filaments that are woven together. The tubular member may also have an outer surface with a longitudinal channel formed therein.

The invention discloses an application of miR-100 sponge in preparation of a medicine for treating type 2 diabetes mellitus. The miR-100 sponge can inhibit miR-100 in a targeted manner and close the expression of miR-100 in beta cells. The nucleic acid construct is further prepared from the nucleic acid construct, AAV8-mmu-miR-100 Sponge (AAV-Sponge) is injected into pancreatic ducts of obese diabetes mellitus mice, after treatment is conducted for 4 weeks, it is found that the sugar tolerance of the mice in a treatment group is improved, the GSIS function of beta cells is improved, and the nucleic acid construct is expected to be further applied to preparation of the medicine for treating the type 2 diabetes mellitus. The problems that current treatment methods for type 2 diabetes mellitus are deficient and the treatment cost is high are solved.

Systems and methods for treating, for example, strictures along a biliary tract and / or pancreatic duct are disclosed. An example system can include a handle (14) having a base, a first carriage (26) translatable relative to the base, and a second carriage (24) translatable relative to the base. A sheath (16) can be coupled to the first carriage. The system can also include a catheter shaft (12) having a proximal region and a steerable distal region. The proximal region can be coupled to the second carriage. A needle can be releasably coupled to the handle. The needle can be configured to pass through tissue to a location along a biliary tract and / or pancreatic duct. The system can also include a steering member (44) having a first end coupled to the steerable distal region of the catheter shaft and a second end disposed adjacent the handle.

The utility model relates to medical instrument technical field especially, and it is a kind of covered stent and implantation system.This covered stent includes support framework and film, wherein: support framework is the hollowed out cylinder structure of peripheral surface, it can be radially compressed and expand;Film is coated on part support framework, and drainage mesh is formed at the region of support framework not being coated by film.Due to film being coated on part support framework, drainage mesh is formed at the region of support framework not being coated by film, bile of gallbladder, bile in common hepatic duct and pancreatic juice in pancreatic duct can enter the inside of covered stent through drainage mesh and reach duodenal papilla, thereby avoiding the phenomenon that bile and pancreatic juice cannot flow out from common bile duct and reach duodenal papilla due to common bile duct being pressed by stent, and simultaneously, a plastic stent does not need to be additionally implanted in common bile duct to help common bile duct drainage, to achieve the purpose of reducing operation cost and operation complexity.

The utility model provides a kind of wire guide calculus extraction net basket, including net basket, guide wire, net basket cap, outer sheath and handle, tail end of guide wire is connected with the head end of net basket cap, net basket cap is placed in the head end outside of outer sheath, net basket is inserted to the inside of outer sheath through the tail end of outer sheath, one end of net basket is connected with the tail end of net basket cap, other end is connected with handle;Handle is located in the tail end outside of outer sheath.The utility model can be inserted through papilla incision knife, SpyGlass or insight pancreatic duct imaging system channel etc.Various instrument channels, realize the calculus extraction treatment of multiple scenes;During the release of net basket, soft guide wire head end crosses stone more easily into the distal bile duct, more conducive to the release of net basket, and net basket can be taken out of stone by pulling back.

An amplifying method of pancreatic cells is provided. The amplifying method includes performing digestion, resuspension, discontinuous density gradient centrifugation treatment and amplifying treatment sequentially. The mammalian pancreatic duct is used as the source of pancreatic precursor-like cells in the amplifying method, and islet cells and acinar cells in the cell clusters obtained by the discontinuous density gradient centrifugation treatment are removed. It is beneficial to improve the yield of the pancreatic precursor-like cells availably, and avoid the ethical restrictions and possible carcinogenic risks caused by using the embryonic stem cells. The amplifying medium used comprises a reprogramming substance composed of several small molecule compounds. It can avoid the risks of non-specific and off-target deletion that are easily caused by the use of the gene-editing methods to change the gene sequence. Also provided is a differentiation method and an application of the pancreatic precursor-like cells obtained by the amplifying method.

The invention relates to the technical field of magnetic resonance imaging, and discloses a thin-layer oblique coronal focusing view diffusion weighted imaging method of a magnetic resonance system, which comprises the following steps of: extracting a three-dimensional space walking path of a target bile duct based on magnetic resonance pancreaticobiliary duct water imaging and a cross section T2 weighted image, performing optimal plane fitting, and determining a personalized oblique coronal scanning plane; in the plane, diffusion weighted imaging is carried out by adopting a small visual field set according to bile duct projection, a layer thickness not higher than 3.0 mm and a low b value not higher than 100 seconds / square millimeters and a high b value not lower than 800 seconds / square millimeters, and echo time is set to a minimum value allowed by a system. Through cooperation of personalized plane positioning, thin-layer high-b-value imaging and intelligent quality control, the problems that conventional magnetic resonance imaging is incomplete in display of an extrahepatic cholangiocarcinoma lesion anatomical structure, low in signal-to-noise ratio, multiple in motion artifacts and difficult to accurately evaluate the longitudinal infiltration range of a tumor are solved.

The invention relates to the technical field of biological medicines, in particular to application of a reagent for inhibiting expression of miR-758-3p in preparation of a medicine for treating pancreatic ductal adenocarcinoma. The reagent is a micro RNA (miRNA) inhibitor, a small interfering RNA (siRNA), an antisense oligonucleotide (ASO) or a combination of the micro RNA inhibitor, the small interfering RNA (siRNA) and the antisense oligonucleotide (ASO) which can down-regulate the expression of the miR-758-3p. The invention also relates to a medicine for treating pancreatic ductal adenocarcinoma, which comprises an effective amount of the reagent and a pharmaceutically acceptable carrier. The medicine is used for inhibiting proliferation, migration and / or invasion of pancreatic duct adenocarcinoma cells. The invention provides a new biomarker and a treatment intervention target for pancreatic ductal adenocarcinoma. And the feasibility of targeted therapy is defined. And the method has a definite conversion prospect.

The invention discloses a bile and pancreatic juice diversion catheter set which comprises guide wires (1), a diversion catheter (2), a pushing catheter (3) and an outer sheath tube (4), the diversion catheter (2) is installed at the head end in the outer sheath tube (4), one end of the pushing catheter (3) is inserted from the tail end of the outer sheath tube (4), the number of the guide wires (1) is two, and the number of the guide wires (1) is two. And the two guide wires penetrate through the shunting catheter (2) and the pushing catheter (3). The device can be arranged in the bile duct and the pancreatic duct, can block pancreatic-bile reflux, does not affect the normal physiological structure and function of the human body, and is suitable for all patients.

The invention discloses a method for analyzing potential mechanisms of EGCG (epigallocatechin gallate) intervening type 2 diabetes mellitus on the basis of network pharmacology. The molecular mechanism of the EGCG is disclosed by integrating multiple omics technologies. The method comprises the following steps: firstly, predicting an EGCG (epigallocatechin gallate) action target spot by utilizing databases such as PubChem and SwisTargetPrediction, carrying out intersection analysis on the EGCG action target spot and a type II diabetes related pathological target spot, and screening out three key genes, namely ALOX5AP, DGAT1 and PLA2G2A; bulk transcriptome sequencing and single cell transcriptome data are combined, GO / KEGG function enrichment, GSEA / GSVA pathway analysis and five algorithms are adopted to quantify glycolipid metabolism characteristics, and it is clear that key targets participate in lipid metabolism regulation and inflammation signal transduction. Furthermore, a communication network between pancreatic duct cells is analyzed through CellChat, the type of a core cell acted by EGCG is positioned, and the high-affinity interaction of the core cell is confirmed.

This invention relates to a novel use of synephrine in the preparation of drugs for treating cholestatic liver disease, belonging to the field of pharmaceutical technology. Cholestatic liver disease is characterized by jaundice and conjugated bilirubin and / or total bilirubin hyperconjugation caused by impaired bilirubin excretion due to various reasons. Its causes include common bile duct stones, pancreatic duct cancer, common bile duct malignant tumors, pancreatic cancer, biliary parasitic diseases, viral hepatitis cirrhosis, alcoholic liver disease, fatty liver disease, drug-induced liver injury, primary biliary cirrhosis, intrahepatic sclerosing cholangitis, and certain congenital diseases such as Dubin-Johnson syndrome and Rotor syndrome. This invention establishes a mouse cholestasis model using bile duct ligation and administers synephrine by gavage to evaluate its protective effect against liver injury. The results showed that synephrine significantly improved jaundice caused by cholestasis, reduced hepatocellular necrosis and inflammatory infiltration caused by cholestasis, alleviated bile duct dilation, decreased serum total bilirubin (TBIL) and direct bilirubin (DBIL), and reduced the levels of total bile acids (BA) in liver tissue and plasma. Furthermore, the above-mentioned effects of synephrine in improving cholestasis showed a clear dose-dependent effect. This invention reveals for the first time the application of synephrine in cholestatic liver disease, demonstrating good safety and promising clinical development prospects.

What is provided is an endoscopic device including: a sheath extending in a longitudinal direction thereof; a treatment tool opening portion that communicates with a treatment tool lumen inserted through the sheath in the longitudinal direction and allows a treatment tool inserted through the treatment tool lumen to project to and retract from a distal end side of the sheath in the longitudinal direction; and a suction opening portion communicating with a suction lumen inserted through the sheath in the longitudinal direction, wherein the treatment tool opening portion and the suction opening portion are provided in an insertion region that is disposed inside bile and pancreatic ducts when the sheath is inserted into the bile and pancreatic ducts, and the suction opening portion is able to suck an inner wall of the bile and pancreatic ducts.

The invention discloses a pancreatic fistula risk assessment system after pancreaticoduodenectomy based on multi-factor analysis, and relates to the technical field of medical information. Comprising a data acquisition module which is used for acquiring preoperative CT images and clinical data of a patient; the feature extraction module is used for quantitatively extracting radiomics features, pancreatic duct diameters and body component indexes from the CT images; the model construction module is used for integrating the features through multivariable logistic regression to construct a prediction model; the verification module is used for resampling through a self-service method and evaluating the performance of the model through an ROC curve; and an output module. According to the method, through multi-factor integration, the accuracy of CR-POPF preoperative prediction is remarkably improved, and the method is superior to a single-index model; and subjective deviation is reduced based on objective data, and clinical availability is improved in a network calculator form.

The utility model provides a kind of double guide wire nipple sphincter incision knife, comprising: outer sheath, handle, first guide wire, second guide wire and wire, first guide wire is inserted to the inside of outer sheath through the pipe wall of outer sheath, and it is worn from the pipe wall of outer sheath;Handle is connected with the tail end of outer sheath, second guide wire is inserted to the inside of outer sheath through handle, and it is worn from the head end of outer sheath;One end of wire is fixedly connected on the pipe wall of outer sheath, the other end is inserted into the inside of outer sheath, and is connected with handle.The utility model uses, assistant can implement guide wire auxiliary nipple sphincter incision knife cannula into pancreatic duct, on the basis of not increasing nipple incision knife pipe diameter, operator can operate second guide wire and insert into common bile duct through pipe wall lateral wall, realize double person multi-angle cannulation, increase the success rate of bile duct cannulation.

The invention relates to the technical field of biological medicine, in particular to an MTA3 small-molecule inhibitor and application thereof in sensitizing chemotherapy effect of gemcitabine pancreatic duct adenocarcinoma. The invention provides a small molecule MTA3i-01 which is obtained through high-throughput virtual screening and structure optimization. The micromolecule MTA3i-01 provided by the invention can specifically interfere with the combination of the MTA3 protein and the CRIP2 gene promoter region, and effectively recover the sensitivity of tumor cells to gemcitabine, thereby significantly enhancing the curative effect of chemotherapy. The tumor growth can be obviously inhibited by the combined treatment of the MTA3i-01 and the gemcitabine, the tumor growth is obviously inhibited by the combined treatment of the MTA3i-01 and the gemcitabine, the combined treatment is obviously superior to that of a gemcitabine single drug group and a MTA3i-01 single drug group, and obvious toxic reaction is not observed, so that the combined scheme has good in-vivo safety and synergistic curative effect.